梅州子宫内膜炎该如何治疗(梅州超导人流大概价格是多少) (今日更新中)

LOS ANGELES, July 5 (Xinhua) -- NASA's Juno spacecraft is 30 days away before its first launch window opens, the Jet Propulsion Laboratory (JPL) announced on Tuesday."One month from today, our first launch window opens at 11:34 a. m. EDT (8:34 a.m. PDT) and lasts 69 minutes," said Jan Chodas, Juno project manager from NASA's JPL in Pasadena, Los Angeles."Our primary launch period is 22 days long, and so if weather or other issues come up on Aug. 5, we have 21 more days to get Juno flying. Once we get Juno into space, it's a five-year cruise to Jupiter.""The launch window is the length of time allotted every day for an attempt to launch the spacecraft," said Chodas. "The launch period is the period of time in days when everything is in the right place to get your mission off to the right start."For a mission like Juno, getting everything in the right place includes considering the size of the rocket and spacecraft, where our home planet -- and in particular Juno's launch pad -- is pointed at any moment, and its location in space relative to other celestial objects like Juno's final target, Jupiter.Juno is scheduled to launch aboard a United Launch Alliance Atlas V rocket from pad 41-C at the Cape Canaveral Air Force Station, Florida.The solar-powered spacecraft will orbit Jupiter's poles 33 times to find out more about the gas giant's origins, structure, atmosphere and magnetosphere and investigate the existence of a solid planetary core.JPL manages the Juno mission for the principal investigator, Scott Bolton, of Southwest Research Institute in San Antonio.The Juno mission is part of the New Frontiers Program managed at NASA's Marshall Space Flight Center in Huntsville, Alaska. Lockheed Martin Space Systems, Denver, built the spacecraft.

HONG KONG, July 19 (Xinhua) -- A gene controlled by male hormone was critical for the growth of liver tumor, leading to a higher incidence of the disease in men than in women, according to the Chinese University of Hong Kong which made the results public on Tuesday.There is a significant gender bias in liver cancer incidence. In Hong Kong, men are three times more likely to develop liver cancer than women. Such phenomenon prompted researchers from the university to carry out a genomic location analysis in liver cancer cells starting from 2008.The researchers discovered, out of 17,000 human genes, that a gene called Cell Cycle-Related Kinase (CCRK) was directly controlled by androgen receptor. They further found that CCRK was critical for the induction of signaling pathway leading to abnormal liver cell growth and tumor formation.The results also reveal that 70 percent of patients with liver cancer were found to produce high levels of CCRK. More importantly, these patients were more likely to have late-stage cancers and lived shorter than those with low CCRK level.Using mouse models, the researchers found that either lowering the level or blocking the signaling pathway of CCRK in liver cancer cells could significantly reduce the tumor growth rate.The study has validated that CCRK is an important gene that has potential to cause liver cancer and the gene can be tested as a new targeted therapy in future.Vice-Chancellor of the university Joseph Sung, who is also team leader of the research project, said the results explained why men have a higher risk of liver cancer than women and helped push ahead with the development of a novel treatment of the disease.The above study results were published online in July in Journal of Clinical Investigation.

WASHINGTON, June 21 (Xinhua) -- A new study from Harvard School of Public Health (HSPH) and University of California, San Francisco, researchers suggests that men with prostate cancer who smoke increase their risk of prostate cancer recurrence and of dying from the disease. The study will be published Wednesday in the Journal of the American Medical Association."In our study, we found similar results for both prostate cancer recurrence and prostate cancer mortality," said Stacey Kenfield, lead author and a research associate in the HSPH Department of Epidemiology. "These data taken together provide further support that smoking may increase risk of prostate cancer progression."Kenfield and her colleagues conducted a prospective observational study of 5,366 men diagnosed with prostate cancer between 1986 and 2006 in the Health Professionals Follow-Up Study. The researchers documented 1,630 deaths, 524 (32 percent) due to prostate cancer, 416 (26 percent) due to cardiovascular disease, and 878 prostate cancer recurrences.The researchers found that men with prostate cancer who were current smokers had a 61 percent increased risk of dying from prostate cancer, and a 61 percent higher risk of recurrence compared with men who never smoked. Smoking was associated with a more aggressive disease at diagnosis, defined as a higher clinical stage or Gleason grade (a measure of prostate cancer severity). However, among men with non-metastatic disease at diagnosis, current smokers had an 80 percent increased risk of dying from prostate cancer.Compared with current smokers, men with prostate cancer who had quit smoking for 10 or more years, or who had quit for less than 10 years but smoked less than 20 pack-years before diagnosis, had prostate cancer mortality risk similar to men who had never smoked. Men who had quit smoking for less than 10 years and had smoked 20 or more pack-years had risks similar to current smokers."These data are exciting because there are few known ways for a man to reduce his risk of dying from prostate cancer," said senior author Edward Giovannucci, professor of nutrition and epidemiology at HSPH. "For smokers, quitting can impact their risk of dying from prostate cancer. This is another reason to not smoke."Prostate cancer is the most frequently diagnosed form of cancer diagnosed in the United States and the second leading cause of cancer death among U.S. men, affecting one in six men during their lifetime. More than two million men in the U.S. and 16 million men worldwide are prostate cancer survivors.

WASHINGTON, June 14 (Xinhua) -- Eating a low-carbohydrate, high- protein diet may reduce the risk of cancer and slow the growth of tumors already present, according to a study published Tuesday in Cancer Research, a journal of the American Association for Cancer Research.The study was conducted in mice, but the scientists involved agree that the strong biological findings are definitive enough that an effect in humans can be considered."This shows that something as simple as a change in diet can have an impact on cancer risk," said lead researcher Gerald Krystal, a scientist at the British Columbia Cancer Research Center.Krystal and his colleagues implanted various strains of mice with human tumor cells or with mouse tumor cells and assigned them to one of two diets. The first diet, a typical Western diet, contained about 55 percent carbohydrate, 23 percent protein and 22 percent fat. The second, which is somewhat like a South Beach diet but higher in protein, contained 15 percent carbohydrate, 58 percent protein and 26 percent fat. They found that the tumor cells grew consistently slower on the second diet.As well, mice genetically predisposed to breast cancer were put on these two diets and almost half of them on the Western diet developed breast cancer within their first year of life while none on the low-carbohydrate, high-protein diet did. Interestingly, only one on the Western diet reached a normal life span ( approximately 2 years), with 70 percent of them dying from cancer while only 30 percent of those on the low-carbohydrate diet developed cancer and more than half these mice reached or exceeded their normal life span.Krystal and colleagues also tested the effect of an mTOR inhibitor, which inhibits cell growth, and a COX-2 inhibitor, which reduces inflammation, on tumor development, and found these agents had an additive effect in the mice fed the low-carbohydrate, high-protein diet.When asked to speculate on the biological mechanism, Krystal said that tumor cells, unlike normal cells, need significantly more glucose to grow and thrive. Restricting carbohydrate intake can significantly limit blood glucose and insulin, a hormone that has been shown in many independent studies to promote tumor growth in both humans and mice.Furthermore, a low-carbohydrate, high-protein diet has the potential to both boost the ability of the immune system to kill cancer cells and prevent obesity, which leads to chronic inflammation and cancer.

BEIJING, Aug. 25 (Xinhua) -- China pledged on Thursday to make more efforts to aid people living in the drought-stricken Horn of Africa in collaboration with the International Committee for the Red Cross (ICRC)."We noticed that the ICRC launched an appeal regarding the situation in the Horn of Africa. The Red Cross Society of China (RCSC) has decided to donate 4 million yuan (about 623,000 U.S. dollars) to the ICRC for its humanitarian aid in the region," said Hua Jianmin, president of the RCSC, while meeting with visiting ICRC President Jakob Kellenberger in Beijing on Thursday.Earlier this month, the RCSC donated 8 million yuan (1.25 million dollars) to famine-plagued countries in the Horn of Africa to be used for emergency humanitarian aid.A donation of 2 million yuan was sent to Kenya through the country's Red Cross organization, while another 2 million went to Ethiopia. The other 4 million yuan was donated to other countries in the region.The Chinese government has decided to provide a total of 90 million yuan (14 million dollars) in emergency food assistance to countries in the Horn of Africa."The Red Cross Society of China is willing to work together with the International Committee for the Red Cross to meet the needs of those who have been affected (by the droughts)," Hua said.Some 12.4 million people in Kenya, Ethiopia, Somalia and other countries in the region are in dire need of food due to a serious drought, the worst to hit the region since the 1980s.

来源：资阳报